AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) ~~The compounds~~ A compound according to the general formula Ia or Ib:



Ia



Ib

wherein in each,

R1 ~~means~~ is H, C_1-C_6 alkyl, cycloalkyl, or C_1-C_4 ~~alkylcycloalkyl,~~ alkylcycloalkyl;

R2 ~~means~~ is C_1-C_{14} alkyl, C_2-C_{14} alkenyl, C_1-C_4 alkylaryl, heteroaryl, C_1-C_4 alkyl heteroaryl, cycloalkyl, C_1-C_4 alkyl-cycloalkyl, heterocycloalkyl, C_1-C_4 alkylheterocycloalkyl, $C_mH_{2m+o-p}Y_p$ ~~(with m = 1 to 6, for o = 1, p = 1 to 2m+o; for m = 2 to 6, o = -1, p = 1 to 2m+o; for m = 4 to 6, o = -2, p = 1 to 2m+o; Y = independently from each other selected from the group consisting of halogen, OH, OR21, NH_2, NHR21, NR21R22, SH, SR21)~~, $CH_2NHCOR21$, $CH_2NHCSR21$, $CH_2S(O)nR21$, with n = 0, 1, 2, $CH_2SCOR21$, CH_2OSO_2-R21, CHO, CH=NOH, CH(OH)R21, -CH=NOR21, -CH=NOCOR21, -CH=NOCH$_2$CONR21R22, -CH=NOCH(CH_3)CONR21R22, -CH=NOC(CH_3)$_2$CONR21R22, -CH=N-NHCO-R23, -CH=N-NHCO-CH_2NHCOR21, -CH=N-O-CH_2NHCOR21, -CH=N-NHCS-R23, -CH=CR24R25 (trans or cis), COOH, COOR21,



CONR21R22, -CH=NR21, -CH=N-NR21R22, , ~~with X' = NR215, O, S, and R211, R212, R213, R214, R215 being independently from each other H or C_1-C_6 alkyl)~~, -CH=N-$NHSO_2$ aryl, or -CH=N-$NHSO_2$ ~~heteroaryl,~~ heteroaryl;

wherein, m is 1 to 6, o is 1, p is 1 to 2m+o;

m is 2 to 6, o is -1, p is 1 to 2m+o; or

m is 4 to 6, o is -2, p is 1 to 2m+o; and

Y independently from each other is selected from the group consisting of halogen, OH, OR21, NH_2, NHR21, NR21R22, SH and SR21; and

wherein X' is NR215, O, or S; and R211, R212, R213, R214, and R215 are independently from each other H or C_1-C_6 alkyl;

R21, R22 are independently from each other C_1-C_{14} alkyl, C_1-C_{14} alkanoyl, C_1-C_6 alkylhydroxy, C_1-C_6 alkylamino, C_1-C_6 alkylamino-C_1-C_6 alkyl, C_1-C_6 alkylamino-di-C_1-C_6 alkyl, cycloalkyl, C_1-C_4 alkylcycloalkyl, heterocycloalkyl, C_1-C_4 alkylheterocycloalkyl, aryl, aryloyl, C_1-C_4 alkylaryl, heteroaryl, heteroaryloyl, C_1-C_4 alkylheteroaryl, cycloalkanoyl, C_1-C_4 alkanoylcycloalkyl, heterocycloalkanoyl, C_1-C_4 alkanoylheterocycloalkyl, C_1-C_4 alkanoylaryl, C_1-C_4 alkanoylheteroaryl, or mono- and di-sugar ~~residues~~ linked through a C atom which would carry an OH ~~residue~~ group in the sugar, wherein the sugars are independently from each other

selected from the group consisting of glucuronic acid and its stereo isomers at all optical C-atoms, aldopentoses, and aldohexoses, including their desoxy compounds ~~(such as e.g. glucose, desoxyglucose, ribose, desoxyribose),~~ ;

R23 independently of R21, ~~has the same meanings as~~ is R21, ~~or~~ CH_2-pyridinium salts, or CH_2-tri-C_1-C_6 alkylammonium ~~salts,~~ salts;

R24 independently of R21, ~~has the same meanings as~~ is R21, ~~or~~ H, CN, $COCH_3$, COOH, COOR21, CONR21R22, NH_2, ~~NHCOR21,~~ or NHCOR21;

R25 independently of R21, ~~has the same meanings as~~ is R21, ~~or~~ H, CN, $COCH_3$, COOH, COOR21, CONR21R22, NH_2, ~~NHCOR21,~~ or NHCOR21;

R24, R25 together ~~mean~~ are C_4-C_8 ~~cycloalkyl,~~ cycloalkyl;

R3 ~~means~~ is H, F, Cl, Br, I, OH, OR31, NO_2, NH_2, NHR31, NR31R32, NHCHO, NHCOR31, NHCOCF3, $CH_{3-m}hal_m$ ~~(with hal = Cl, F, especially F, and m = 1, 2, 3),~~ or OCOR31, wherein hal is Cl or F and m is 1, 2 or 3;

R31, 32 independently from each other ~~mean~~ are C_1-C_6 ~~alkyl,~~ alkyl;

R5, R6 Independently from each other ~~mean~~ are H, C_1-C_{14} alkyl, C_2-C_{14} alkenyl, aryl, C_1-C_4 alkylaryl, heteroaryl, C_1-C_4 alkylheteroaryl, cycloalkyl, C_1-C_4 alkylcycloalkyl, heterocycloalkyl, C_1-C_4 alkylheterocycloalkyl, $C_mH_{2m+o-p}Y_p$ ~~(with m = 1 to 6, for o = 1, p = 1 to 2m+o; for m = 2 to 6, o = -1, p = 1 to 2m+o; for m = 4 to 6, o = -2, p = 1 to 2m+o; Y = independently selected from the group consisting of halogen, OH, OR21, NH_2, NHR21, NR21R22, SH, SR21)~~, or R5 and R6, together with X_1-C-C-X_2, form a ring with 5, 6, or 7 members,
wherein, m is 1 to 6, o is 1, p is 1 to 2m+o;
m is 2 to 6, o is -1, p is 1 to 2m+o; or

m is 4 to 6, o is -2, p is 1 to 2m+o; and

Y independently from each other is selected from the group consisting of halogen, OH, OR21, NH_2, NHR21, NR21R22, SH and SR21;

R4, R7, R8 independently from each other ~~mean~~ are H, C_1-C_6 alkyl, ~~CO-R41,~~ CO-R41;

R41 independently from R21 ~~has the same meanings as R21,~~ is R21;

X1 ~~means~~ is O, S, NH, N-C_1-C_8 alkyl, ~~N-cycloalkyl,~~ or N-cycloalkyl;

X2 ~~means~~ is O, S, NH, N-C_1-C_8 alkyl, ~~N-cycloalkyl,~~ or N-cycloalkyl;

Y1 ~~means~~ is O, or N-R9, wherein R9 ~~can~~, independently from R5, ~~adopt the same meanings as R5,~~ is R5;

Y2 ~~means~~ is O, or N-R10, wherein R10 ~~can~~, independently from R5, ~~adopt the same meanings as R5,~~ is R5;

and, if Y1 or Y2 are N-R9 or N-R10, X2-R6 may be ~~H,~~ H;

Y3 ~~means~~ is O, S, ~~NH,~~ or NH;

~~as well their stereoisomers, tautomers, and their physiologically tolerable salts or inclusion compounds~~ or a stereoisomer, tautomer or physiologically tolerable salt thereof.

2. (Currently amended) The ~~compounds~~ compound according to claim 1, wherein Formula Ia or Ib adopt the stereochemistry of Formula IIa or IIb



IIa



IIb

3. (Canceled)

4. (Currently amended) The ~~compounds~~ compound according to ~~one of~~ claim 1, wherein

R1 ~~means~~ is H, C_1-C_5 alkyl, ~~cycloalkyl, especially H,~~ or cycloalkyl;

R2 ~~means~~ is C_1-C_5 alkyl, C_1-C_4 alkylaryl, C_2-C_5 alkenyl, heteroaryl, C_1-C_4 alkylheteroaryl, CHF_2, CF_3, polyol side chain, ~~particularly~~ CHOH-CHOH-CHOH-CHOH-CH_3, CHOH-CHOH-CH=CH-CH_3, CH=CH-CHOH-CHOH-CH_3, CH_2Y ~~(Y = F, Cl, Br, I),~~ CH_2NH_2, $CH_2NR21R22$, $CH_2NHCOR23$, $CH_2NHCSR23$, CH_2SH, $CH_2S(O)nR21$, ~~with n = 0, 1, 2,~~ $CH_2SCOR21$, ~~particularly~~ CH_2OH, CH_2OR21, CH_2OSO_2-R21, ~~particularly~~ CHO, $CH(OR21)_2$, $CH(SR21)_2$,

CN, CH=NOH, CH=NOR21, CH=NOCOR21, CH=N-NHCO-R23, CH=CR24, R25 (trans or cis), ~~particularly~~ COOH ~~(particularly their physiologically tolerable salts),~~ COOR21,



CONR21R22, -CH=NR21, -CH=N-NR21R22, ,

~~(with X' = NR215, O, S, and R211, R212, R213, R214, R215 being independently from each other H or C_1-C_6 alkyl),~~ -CH=N-$NHSO_2$ aryl, -CH=N-$NHSO_2$ heteroaryl, or CH=N-NHCO-R23,

wherein Y is F, Cl, Br or I; and

wherein X' is NR215, O, or S; and R211, R212, R213, R214, and R215 are independently from each other H or C_1-C_6 alkyl;

R21, R22 independently from each other ~~mean~~ are C_1-C_6 alkyl, cycloalkyl, aryl, C_1-C_4 alkylaryl, heteroaryl, ~~C_1-C_4 alkylheteroaryl,~~ or C_1-C_4 alkylheteroaryl;

R23 independently of R21, ~~has the same meanings as~~ is R21, ~~or~~ a CH_2-pyridinium ~~salts,~~ salt, or a CH_2-tri-C_1-C_6 alkylammonium ~~salts,~~ salt;

R24 independently of R21, ~~has the same meanings as~~ is R21, or H, CN, $COCH_3$, COOH, COOR21, CONR21R22, NH_2, ~~NHCOR21,~~ or NHCOR21;

R25 independently of R21, ~~has the same meanings as~~ is R21, or H, CN, $COCH_3$, COOH, COOR21, CONR21R22, NH_2, ~~NHCOR21,~~ or NHCOR21;

R24, R25 together ~~mean C_4-C_8 cycloalkyl,~~ are C_4-C_8 cycloalkyl;

R3 ~~means~~ is F, Cl, Br, I, NO_2, NH_2, ~~NHCOR31,~~ or NHCOR31;

R31 independently from each other ~~means C_1-C_6 alkyl,~~ is C_1-C_6 alkyl;

R5, R6 independently from each other ~~mean~~ are H, C_1-C_{14} alkyl, C_2-C_{14} alkenyl, aryl, C_1-C_4 alkylaryl, heteroaryl, C_1-C_4 alkylheteroaryl, cycloalkyl, C_1-C_4 alkylcycloalkyl, heterocycloalkyl, C_1-C_4 alkylheterocycloalkyl, $C_mH_{2m+o-p}Y_p$ ~~(with m = 1 to 6, for o = 1, p = 1 to 2m+o; for m = 2 to 6, o = -1, p = 1 to 2m+o; for m = 4 to 6, o = -2, p = 1 to 2m+o; Y = independently selected from the group consisting of halogen, OH, OR21, NH_2, NHR21, NR21R22, SH, SR21)~~, or R5 and R6, together with X_1-C-C-X_2, form a ring with 5, 6, or 7 members,

wherein, m is 1 to 6, o is 1, p is 1 to 2m+o;

m is 2 to 6, o is -1, p is 1 to 2m+o; or

m is 4 to 6, o is -2, p is 1 to 2m+o; and

Y independently from each other is selected from the group consisting of halogen, OH, OR21, NH_2, NHR21, NR21R22, SH and SR21;

R4, R7, R8 independently from each other ~~mean~~ are H, C_1-C_6 alkyl, ~~CO-R41,~~ or CO-R41;

R41 independently from R21 ~~has the same meanings as R21,~~ is R21;

Y3 ~~means O, S, preferably O,~~ is O or S;

~~as well their stereoisomers, tautomers, and their physiologically tolerable salts or inclusion compounds.~~ or a stereoisomer, tautomer or physiologically tolerable salt thereof.

5. (Currently amended) The compounds according to claim 1 in the form of their inclusion compounds with cyclodextrin~~, particularly alpha-cyclodextrin~~.

Claims 6-12. (Canceled)

13. (Currently amended) The ~~compounds~~ compound according to claim 2 wherein

R1 ~~means~~ is H, C_1-C_5 alkyl, or cycloalkyl~~, especially H,~~;

R2 ~~means~~ is C_1-C_5 alkyl, C_1-C_4 alkylaryl, C_2-C_5 alkenyl, heteroaryl, C_1-C_4 alkylheteroaryl, CHF_2, CF_3, polyol side chain, ~~particularly~~ CHOH-CHOH-CHOH-CHOH-CH_3, CHOH-CHOH-CH=CH-CH_3, CH=CH-CHOH-CHOH-CH_3, CH_2Y ~~(Y = F, Cl, Br, I)~~, CH_2NH_2, $CH_2NR21R22$, $CH_2NHCOR23$, $CH_2NHCSR23$, CH_2SH, $CH_2S(O)nR21$, ~~with n = 0, 1, 2,~~ $CH_2SCOR21$, ~~particularly~~ CH_2OH, CH_2OR21, CH_2OSO_2-R21, ~~particularly~~ CHO, $CH(OR21)_2$, $CH(SR21)_2$, CN, CH=NOH, CH=NOR21, CH=NOCOR21, CH=N-NHCO-R23, CH=CR24, R25 (trans or cis), ~~particularly~~ COOH ~~(particularly their physiologically tolerable salts)~~, COOR21,



CONR21R22, -CH=NR21, -CH=N-NR21R22, , ~~(with X' = NR215, O, S, and R211, R212, R213, R214, R215 being independently from each other H or C_1-C_6 alkyl),~~ -CH=N-$NHSO_2$ aryl, -CH=N-$NHSO_2$ heteroaryl, CH=N-NHCO-R23,

wherein Y is F, Cl, Br or I;

n is 0, 1 or 2; and

wherein X' is NR215, O, or S; and R211, R212, R213, R214, and R215 are independently from each other H or C_1-C_6 alkyl;

R21, R22 independently from each other ~~mean~~ are C_1-C_6 alkyl, cycloalkyl, aryl, C_1-C_4 alkylaryl, heteroaryl, ~~C_1-C_4 alkylheteroaryl,~~ or C_1-C_4alkylheteroaryl;

R23 independently of R21, ~~has the same meanings as~~ is R21, ~~or~~ a CH_2-pyridinium ~~salts,~~ salt, or a CH_2-tri-C_1-C_6 alkylammonium ~~salts,~~ salt;

R24 independently of R21, ~~has the same meanings as~~ is R21, ~~or~~ H, CN, $COCH_3$, COOH, COOR21, CONR21R22, NH_2, ~~NHCOR21,~~ or NHCOR21;

R25 independently of R21, ~~has the same meanings as~~ is R21, ~~or~~ H, CN, $COCH_3$, COOH, COOR21, CONR21R22, NH_2, ~~NHCOR21,~~ or NHCOR21;

R24, R25 together ~~mean C_4-C_8-cycloalkyl,~~ are C_4-C_8 cycloalkyl;

R3 ~~means~~ is F, Cl, Br, I, NO_2, NH_2, ~~NHCOR31,~~ or NHCOR31;

R31 independently from each other ~~means C_1-C_6-alkyl,~~ is C_1-C_6 alkyl;

R5, R6 independently from each other ~~mean~~ are H, C_1-C_{14} alkyl, C_2-C_{14} alkenyl, aryl, C_1-C_4 alkylaryl, heteroaryl, C_1-C_4 alkylheteroaryl, cycloalkyl, C_1-C_4 alkylcycloalkyl, heterocycloalkyl, C_1-C_4 alkylheterocycloalkyl, $C_mH_{2m+o-p}Y_p$ ~~(with m = 1 to 6, for o = 1, p = 1 to 2m+o; for m = 2 to 6, o = -1, p = 1 to 2m+o; for m = 4 to 6, o = -2, p = 1 to 2m+o; Y = independently selected from the group consisting of halogen, OH, OR21, NH_2, NHR21, NR21R22, SH, SR21),~~ or R5 and R6, together with X_1-C-C-X_2, form a ring with 5, 6, or 7 members,

wherein, m is 1 to 6, o is 1, p is 1 to 2m+o;

m is 2 to 6, o is -1, p is 1 to 2m+o; or

m is 4 to 6, o is -2, p is 1 to 2m+o; and

Y independently from each other is selected from the group consisting of halogen, OH, OR21, NH_2, NHR21, NR21R22, SH and SR21;

R4, R7, R8 independently from each other ~~mean~~ are H, C_1-C_6 alkyl, ~~CO-R41,~~ or CO-R41;

R41 independently from R21 ~~has the same meanings as R21,~~ is R21;

Y3 ~~means O, S, preferably O,~~ is O or S;

~~as well their stereoisomers, tautomers, and their physiologically tolerable salts or inclusion compounds~~ or a stereoisomer, tautomer or physiologically tolerable salt thereof.

Claims 14 – 15 (Canceled)

16. (New) A method of treating a tumor comprising the step of administering to a patient having a tumor selected from the group consisting of lung, renal, prostate, uterine, melanoma and breast tumors an amount of a compound of claim 1 effective to treat said tumor.

17. (New) The method of claim 16 wherein said tumor is a lung tumor.

18. (New) The method of claim 16 wherein said tumor is a renal tumor.

19. (New) The method of claim 16 wherein said tumor is a prostate tumor.

20. (New) The method of claim 16 wherein said tumor is a uterine tumor.

21. (New) The method of claim 16 wherein said tumor is a melanoma.

22. (New) The method of claim 16 wherein said tumor is a breast tumor.

23. (New) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or adjuvant.

24. (New) A method of treating a tumor comprising the step of administering to a patient having a tumor selected from the group consisting of lung, renal, prostate, uterine, melanoma and breast tumors an amount of a compound of claim 2 effective to treat said tumor.

25. (New) The method of claim 24 wherein said tumor is a lung tumor.

26. (New) The method of claim 24 wherein said tumor is a renal tumor.

27. (New) The method of claim 24 wherein said tumor is a prostate tumor.

28. (New) The method of claim 24 wherein said tumor is a uterine tumor.

29. (New) The method of claim 24 wherein said tumor is a melanoma.

30. (New) The method of claim 24 wherein said tumor is a breast tumor.

31. (New) A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier or adjuvant.